Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Y Lecrubier

Showing results (1-10 of 129) with videos related to

Pageof 13
Sort By:
International Clinical Psychopharmacology|March 1, 1995
Clinical utility of venlafaxine in comparison with other antidepressantsY Lecrubier
European Psychiatry : the Journal of the Association of European Psychiatrists|December 1, 2001
The influence of comorbidity on the prevalence of suicidal behaviourY Lecrubier
Drug Safety|April 1, 1994
Risk-benefit assessment of newer versus older monoamine oxidase (MAO) inhibitorsY Lecrubier
The Journal of Clinical Psychiatry|July 11, 2002
The burden of depression and anxiety in general medicineY Lecrubier
La Nouvelle Presse Medicale|September 24, 1977
[Antidepressive effect of a beta adrenergic stimulant]Y Lecrubier
International Clinical Psychopharmacology|March 17, 2001
Is amisulpride an 'atypical' atypical antipsychotic agent?Y Lecrubier
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|December 15, 2000
Depressive illness and disabilityY Lecrubier
European Psychiatry : the Journal of the Association of European Psychiatrists|February 7, 2006
The biological, functional and personal consequences of stressY Lecrubier
International Clinical Psychopharmacology|November 17, 1998
Is depression under-recognised and undertreated?Y Lecrubier
The Journal of Clinical Psychiatry|July 4, 2001
Prescribing patterns for depression and anxiety worldwideY Lecrubier
Pageof 13

Showing results (1-10 of 129) with videos related to

Sort By:
Pageof 13
International Clinical Psychopharmacology|March 1, 1995
Clinical utility of venlafaxine in comparison with other antidepressantsY Lecrubier
European Psychiatry : the Journal of the Association of European Psychiatrists|December 1, 2001
The influence of comorbidity on the prevalence of suicidal behaviourY Lecrubier
Drug Safety|April 1, 1994
Risk-benefit assessment of newer versus older monoamine oxidase (MAO) inhibitorsY Lecrubier
The Journal of Clinical Psychiatry|July 11, 2002
The burden of depression and anxiety in general medicineY Lecrubier
La Nouvelle Presse Medicale|September 24, 1977
[Antidepressive effect of a beta adrenergic stimulant]Y Lecrubier
International Clinical Psychopharmacology|March 17, 2001
Is amisulpride an 'atypical' atypical antipsychotic agent?Y Lecrubier
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|December 15, 2000
Depressive illness and disabilityY Lecrubier
European Psychiatry : the Journal of the Association of European Psychiatrists|February 7, 2006
The biological, functional and personal consequences of stressY Lecrubier
International Clinical Psychopharmacology|November 17, 1998
Is depression under-recognised and undertreated?Y Lecrubier
The Journal of Clinical Psychiatry|July 4, 2001
Prescribing patterns for depression and anxiety worldwideY Lecrubier
Pageof 13